New treatments for HIV-1 in patients with tuberculosis in South Africa
Official title: Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa
Funded at Centre/aids Programme/res/south Africa · NIH-11143963 · Data updated 2026-11-12
This study is looking at how well certain HIV medications work for people who also have tuberculosis, especially in South Africa where many have both infections, and it aims to find the best and safest ways to use these treatments for both adults and kids.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Centre/aids Programme/res/south Africa NIH-funded |
| Lab location | 1 site (Durban, SOUTH AFRICA) |
| Project start | August 3, 2020 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $200,932 |
| NIH project number | 3R01AI152142-05S1 |
| Project ID | NIH-11143963 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with HIV-1 who are also undergoing treatment for tuberculosis, particularly those in South Africa.
✕Less likely to help
Patients without HIV-1 or those not undergoing treatment for tuberculosis may not benefit from this research.
What this research studies
This research investigates the effectiveness of second-generation integrase strand transfer inhibitors (InSTIs) like dolutegravir and bictegravir for treating HIV-1 in patients who are also being treated for tuberculosis (TB). Given the high rates of HIV and TB co-infection in South Africa, the study aims to determine safe and effective dosing strategies for both adults and children, particularly those under 20 kg. The research will assess how these medications interact with rifampicin, a common TB treatment, to ensure optimal care for patients with these dual infections.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with HIV-1 and TB co-infection, enhancing their health outcomes.
How similar studies have gone: Previous research has shown success with integrase strand transfer inhibitors in treating HIV, but this specific approach for co-infected patients is novel.
Where this research is happening
-
Centre/aids Programme/res/south Africa
Durban, South Africa Active
Researchers
- Principal investigator: Naidoo, Anushka — Centre/aids Programme/res/south Africa
- Study coordinator: Naidoo, Anushka
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.